Friday, February 12, 2016 3:37:02 PM
Mr. Karras stated, “Timing is everything, and I see this opportunity with Easton Pharmaceuticals as an extremely high-growth undertaking. What especially excites me is that Easton is in a ground-floor position to leverage its partnerships in the Women’s Health arena and make a major impact in the market with the launch of a suite of patented, in-licensed products in Latin America, a unique position when one considers these same licenses were negotiated for in other territories by some of the largest pharma companies in the world.” Mr. Karras further commented, “Latin America is a very high-growth region for the pharmaceutical industry and I can see additional opportunities for Easton revenues in generic cancer drug sales, as well as with the development of its proprietary cancer compounds. We intend to not only grow in Latin America but across the world in other markets such as the Middle East, and even North America, with some of the other unique product offerings Easton has within the Women’s Health industry.”
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM